To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...

Jury selection for his trial starts Monday. Here is a timeline of major events in his rise and fall: 1990: Combs, then a student at Howard University, gets his start in the music business with an ...

Here's a timeline of their relationship. Gates Ventures declined to comment when reached by Business Insider. October 2021: Gates and Hurd, both avid tennis fans, ran in similar circles before ...

The Los Angeles Angels have placed All-Star right fielder Mike Trout back on the injured list. Trout sustained a season-ending meniscus tear in April last season. He was healthy for Opening Day ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Here's a timeline of their recent missteps: The NFL issued two fines -- $200,000 to the Falcons and $100,000 to the team's new defensive coordinator, Jeff Ulbrich -- after Ulbrich's son ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

The first 100 days of President Trump’s second term has moved at a breakneck speed, ushering in dramatic changes to the federal government and turbulent crackdowns on immigration, trade and ...

While we expect it can eventually get approval, the timeline is unclear. While Regeneron's Praluent has entered the multibillion-dollar cholesterol-lowering market, it faces stiff competition from ...

Here’s everything we know so far about the upcoming OnePlus 13s phone, including its expected launch timeline, price, specifications, and more. From the teaser, it looks like the OnePlus 13s ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Regeneron faced mixed results in Q1 2025 with challenges in its retinal franchise offset by strong pipeline progress and Dupixent’s robust performance. The company remains focused on resolving ...